cipla

cipla

Cipla, Solar Pharma ink non-exclusive settlement with Takeda on acid-reflux drug

by

Drugmakers Cipla and Solar Pharma have signed non-exclusive patent license agreements with Takeda Pharmaceutical Firm Restricted, respectively, for ‘Vonoprazan’ for India. The drug is used to deal with acid-related diseases amongst sufferers. Cipla and Solar Pharma will independently commercialise the drug in India below their respective trademark manufacturers. Earlier this month, Torrent Pharma had additionally … Read more

Inventory that can see motion in the present day: 27 march 2024

by

In accordance with media buzz, Normal Chartered Financial institution-corporate banking is more likely to promote its whole 7.18 per cent stake in Central Depository Providers (India) Ltd (CDSL) and the ground worth has been fastened at ₹1,672 a share. Non-public fairness agency Olympus plans to promote a 9.8 per cent stake in Aster DM Healthcare … Read more

Indian Pharma firms: Do pipelines justify valuation assigned to US enterprise?

by

The main Indian pharma firms function from three major markets: India, the US and different rising markets (EM). In our earlier Massive Story on Indian Pharma, in June 2022, we highlighted the robustness of branded markets (India and rising markets) in comparison with the challenges in US generics. We additionally mentioned the assorted pathways firms … Read more

Solar Pharma, Zydus, Cipla, Torrent Pharma, Dr. Reddy’s: How Indian pharma is Gearing Up for M&A

by

Torrent Pharma and Dr.Reddy’s eyeing promoter stake in Cipla would possibly simply be the beginning of an acquisition spree within the pharma area. We consider Indian Pharma could now flex its monetary muscle for each large and small offers, with sectoral sentiments on a excessive, stability sheets robust and all enterprise segments gathering momentum. Firms … Read more

Chart Check: This pharma company forms BAT pattern; target seen at Rs 1,000

by

[ad_1] rose a little over 2 per cent compared to about 7 per cent gain seen in the Nifty50 in the same period, but technical parameters suggest that the stock could see a bounce back towards Rs 1,000 levels in next 3-5 weeks, suggest experts. The pharma company with a market capitalisation of more than … Read more